相关实验视频
Updated: May 17, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
对olaparib的药理动力学提升:多中心,开放,随机,非劣等性试验 (PROACTIVE-B) 的研究协议
Joanneke K Overbeek1, Niels A D Guchelaar2, Ma Ida Mohmaed Ali3
1Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
与cobicistat一起提高olaparib的药理动力学效果可能会降低卵巢癌患者的副作用和成本. 该策略的目标是与标准olaparib单一疗法相比,有效性和耐受性不低于标准olaparib单一疗法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 药物动力学 (PK) 提升有意使用药物相互作用来增加药物暴露.
- 增强CYP3A基质抗癌药物olaparib,可能会降低其变异性,副作用和成本.
- 这项PROACTIVE-B研究建立在PROACTIVE-A关于足够的增强暴露的研究结果之上.
研究的目的:
- 为了评估强化olaparib治疗与标准olaparib单独治疗的有效性和毒性不劣.
- 评估耐受性,通过因毒性而减少剂量来定义.
- 在卵巢癌患者中通过12个月的无进展生存期来衡量疗效.
主要方法:
- 一个全国性的,多中心的,前性的,随机的,非劣等性试验 (PROACTIVE-B).
- 142名患者 (128名BRCA +,高度,FIGO III/IV卵巢癌患者) 随机分别接受olaparib 300 mg两次或olaparib 100 mg两次与cobicistat 150 mg两次.
- 共同的主要目标:耐受性和疗效;次要目标:健康状况,患者满意度和成本效益.
主要成果:
- 该研究旨在确定有效性和毒性方面的非劣等性.
- 关于非劣等性的具体结果正在等待试验完成.
结论:
- 奥拉巴里布的PK增强为减少剂量,可变性和副作用的有希望的策略.
- 这种方法可能会导致更容易获得和负担得起的抗癌治疗.
- 来自PROACTIVE-B的进一步结果将证实强化olaparib治疗的临床实用性.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Analysis of Population Pharmacokinetic Data
Clinical Trials: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Preclinical Development: Overview